Contents. Corporate Data. 01 Contents / Corporate Data / Segments. 02 Results of Operations (Consolidated)

Transcription

1

2 Contents Corporate Data (as of March 31, 217) 1 Contents / Corporate Data / Segments NAME ROHTO Pharmaceutical Co., Ltd. 2 Results of Operations (Consolidated) Originated February 22, Mainly Financial Indicators (Consolidated) Established September 15, Net Sales by Business Segments (Consolidated) Paid-in-capital 6,415,563,351 5 Net Sales by Reportable Segments (Consolidated) 6 Expenses (Consolidated) 7 Financial Position (Consolidated) Number of Employees Business line Headquarter 1,562 (Non-Consolidated), 6,635 (Consolidated) Production, processing and sales of medicines, and other business Tatsumi-nishi, Ikuno-ku, Osaka , Japan 8 Per Share Information (Consolidated Non-consolidated) 9 Consolidated Balance Sheets (Summary) 1 Consolidated Balance Sheets (Summary) Segments 11 Consolidated Statements of Income (Summary) / Consolidated Statements of Comprehensive Income (Summary) 12 Consolidated Statements of Cash Flows (Summary) 13 Non-Consolidated Financial Statements (Summary) 14 Stock information Eye care products Skincare products Internal Medicines Others Eye drops, eyewash preparations, contact lens products, etc. Dermal medicines, lip balm, sunscreens, functional cosmetics, etc. Gastrointestinal medicines, Chinese herbal medicine, Functional display food, etc. In-vitro test kits, hay fever products, etc. 1

3 Results of Operations (Consolidated) Net Sales 115,472 12, , , , ,16 154,599 Change (%) Gross Profit 67,938 7,495 75,873 86,157 9,599 99,226 91,344 Share of Net Sales (%) Selling, General and Administrative Expenses 54,832 56,871 61,493 69,336 77,44 83,543 75,893 Share of Net Sales (%) Operating Income 13,15 13,624 14,38 16,821 13,159 15,683 15,451 Share of Net Sales (%) Ordinary Income 13,293 13,684 14,73 17,1 14,98 15,339 15,964 Share of Net Sales (%) Profit attributable to owners of parent 7,966 8,184 8,87 8,947 8,631 9,98 1,11 Share of Net Sales (%) Net Sales Operating Income Ordinary Income Profit attributable to owners of parent 18, 15, 1 9, 6, 3, 167,16 16,821 17,1 143, , ,599 16, 129,146 13,15 13,293 13,624 13, ,472 12,292 14,38 14,73 15,683 13,159 14,98 15,339 15,451 15,964 12, 9,98 1,11 8,947 7,966 8,184 8,87 8,631 8, 4, 211/3 212/3 213/3 214/3 215/3 216/3 217/3 2

4 Mainly Financial Indicators (Consolidated) Profitability indicators ROA: Return on Assets (%) ROE: Return on Equity (%) Efficiency indicators Total Asset Turnover (Times) Trade Receivable Turnover (Times) Inventory Turnover (Times) Stability indicators Current Ratio (%) Owners' Equity Ratio (%) Interest Coverage Ratio (Times) Debt-to-Equity Ratio (Times) (Notes) Return on Assets=Ordinary Income/Total Assets (Yearly Average) 1(%) Return on Equity=(Net Income/Average Total Owners' Equity) 1(%) Total Asset Turnover=Net Sales/Average Total Assets (Times) Trade Receivable Turnover=Net Sales/Average Trade Receivable (Times) Inventory Turnover=Net Sales/Average Inventories (Times) Current Ratio=(Current Assets/Current Liabilities) 1(%) Owners' Equity Ratio=(Owners' Equity/Total Assets) 1 (%) Interest Coverage Ratio=Operating Cash Flow (before interests and taxes paid)/interest Expenses (Times) Debt-to-Equity Ratio=(Short-Term Debt+Long-Term Debt)/Net Assets (Shareholders' Equity, until 25/3) Return on Assets Return on Equity (%) 14 (%) /3 212/3 213/3 214/3 215/3 216/3 217/3 3

5 Net Sales by Business Segments (Consolidated) Net Sales in Eye Care Products Business 26,44 25,38 27,251 27,845 28,77 31,944 31,82 Net Sales in Skincare Products Business 68,265 73,777 81,168 94,734 11, ,327 11,844 Net Sales in Internal Medicines Business 15,988 16,512 16,35 17,468 17,27 17,118 17,2 Net Sales in Others Business 4,814 4,694 4,376 3,773 3,85 4,626 3,734 Total 115,472 12, , , , ,16 154,599 Net Sales in Eye Care Products Business Net Sales in Internal Medicines Business 4, 3, 26,44 25,38 27,251 27,845 28,77 31,944 31,82 15, 15,988 16,512 16,35 17,468 17,27 17,118 17,2 1, Net Sales in Eye Care Products Business Net Sales in Skincare Products Business 1, 5, Net Sales in Internal Medicines Business 1 1, 8, 6, 4, Net Sales in Skincare Products Business Net Sales in Others Business 113,327 1, 11,946 11,844 94,734 81,168 7,5 73,777 68,265 4,814 5, 4,694 4,376 4,626 3,773 3,85 3,734 2,5 Net Sales in Others Business Composition of Net Sales by Business Segments Others Business Internal 2.4 % Medicines Business 11.1% 217/3 Skincare Products Business 65.9% Eye Care Products Business 2.6% 211/3 212/3 213/3 214/3 215/3 216/3 217/3 4

6 Net Sales by Reportable Segments (Consolidated) Net Sales in Japan 83,994 85,387 89,641 91,772 9,35 96,937 96,884 Net Sales in America 6,77 5,574 5,619 6,288 7,478 8,378 6,96 Net Sales in Europe 4,15 3,914 3,962 4,81 6,322 8,8 7,26 Net Sales in Asia 2,121 24,14 28,179 39,19 45,616 51,621 41,899 Net Sales in RoW 1,262 1,42 1,742 1,85 2,8 2,71 1,882 Total 115,472 12, , , , ,16 154,599 Net Sales in Japan Net Sales in Europe 1, 8, 6, 4, 83,994 85,387 89,641 91,772 9,35 96,937 96,884 1, 7,5 5, 4,15 3,914 3,962 4,81 6,322 8,8 7,26 Net Sales in Japan Net Sales in America 12, 1, 8, 6, 4, 2, 2,5 Net Sales in America Net Sales in Asia 6, 51,621 5, 45,616 8,378 41,899 39,19 7,478 4, 6,96 6,77 6,288 5,574 5,619 3, 28,179 24,14 2,121 1, Net Sales in Europe Net Sales in Asia Net Sales in RoW Composition of Net Sales by Reportable Segments Net Sales in Asia 27.1% Net Sales in Europe 4.5% Net Sales in America 4.5% Net Sales in RoW 1.2% 217/3 Net Sales in Japan 62.7% 5

7 Expenses (Consolidated) R&D Expenses 3,697 3,717 4,62 4,547 5,585 5,811 6,123 Advertising Expenses 17,331 18,228 19,437 22,986 25,628 26,815 22,255 Promotion Expenses 13,837 14,68 15,794 17,261 19,34 21,173 18,614 Employees (People) 5,21 5,347 5,518 5,845 6,426 6,642 6,635 Depreciation 4,117 4,744 5,256 5,735 6,59 6,44 5,552 Interest and Dividend Income Interest Expenses Capital Expenditures 8,671 8,412 6,7 7,87 4,196 4,512 4,99 R&D Expenses Advertising Expenses Promotion Expenses Depreciation Capital Expenditures 7, 3, 12, 26,815 6,123 25,628 6, 5,811 5,585 25, 1, 22,986 22,255 21,173 8,671 8,412 5, 4,547 19,437 19,34 7,87 18,228 18,614 8, 4,62 17,331 17,261 4, 3,697 3,717 15,794 14,68 6,7 6,59 6,44 15, 13,837 6, 5,735 5,552 5,256 3, 4,744 4,512 4,117 4,196 4,99 1, 4, 2, 1, 5, 2, 211/3 212/3 213/3 214/3 215/3 216/3 217/3 6

8 Financial Position (Consolidated) Total Assets 126, ,8 15, , ,59 179, ,543 Net Assets 77,911 83,627 93,771 98,627 11, , ,436 Interest Bearing Debt 9,98 11,138 9,748 12,567 12,138 8,25 7,916 Interest Bearing Debt to Total Liabilities and Net Assets (%) Net Cash Provided by Operating Activities 12,924 1,391 16,72 18,661 11,292 11,324 13,428 Net Cash Used in Investing Activities 8,587 9,65 1,595 12,62 9,24 6,66 9,511 Net Cash Used in Financing Activities 3,31 8 3,48 5,211 3,375 5,898 2,335 Cash and Cash Equivalents at End of Year 14,5 15,381 19,867 23,26 25,93 22,495 23,466 (Notes) Interest Bearing Debt to Total Liabilities and Net Assets=(Short-Term Debt+Long-Term Debt)/Total Assets 1(%) Total Assets Net Assets Interest Bearing Debt Interest Bearing Debt to Total Liabilities and Net Assets Net Cash Provided by Operating Activities Net Cash Used in Investing Activities 2, 177,59 179, , ,249 15,643 15, 136,8 126, ,436 11, ,271 98,627 1, 93,771 83,627 77,911 5, (%) 15, 3 12,567 12,138 12, 11, ,748 9,98 9, 8,25 7, , , , 15, 1, 5, -5, -1, -15, 12,924-8,587 18,661 16,72 1,391-9,65-1,595 13,428 11,292 11,324-6,66-9,24-9,511-12,62 211/3 212/3 213/3-12, 214/3 215/3 216/3 217/3 7

9 Per Share Information(Consolidated Non-consolidated) Net Income per Share ( ) Price-Earnings Ratio (Times) Net Assets per Share ( ) ,3.96 Price-Book Value Ratio (Times) Dividends per Share ( ) Dividend Payout Ratio (%) Number of Shares Issued and Outstanding (Thousands) 117,97 117, , , , , ,936 Stock Price at Year-End ( ) 891 1,33 1,288 1,822 1,78 2,5 2,86 (Notes) Net Income per Share=Net Income/Average Total Number of Shares lssued and Outstanding ( ) Price-Earnings Ratio=Stock Price at Year-End/Net Income per Share (Times) Net Assets per Share=Net Assets/Total Number of Shares lssued and Outstanding ( ) Price-Book Value Ratio=Stock Price at Year-End/Net Assets per Share (Times) Dividends per Share=Total Cash Dividends/Average Total Number of Shares lssued and Outstanding ( ) Dividend Payout Ratio=(Total Cash Dividends per Share/Net Income per Share) 1 (%) Net Income per Share Net Assets per Share Price-Book Value Ratio Dividends per Share Dividend Payout Ratio (yen) (yen) (Times) (yen) (%) 1 1, , /3. 212/3 213/3 214/3 215/3 216/3 217/3 8

10 Consolidated Balance Sheets (Summary) 9 (millions of yen) ASSETS Current assets 65,12 71,28 77,467 82,981 93,692 11,752 1,948 Cash and cash equivalents 14,16 15,381 19,868 23,28 25,733 23,73 23,924 Notes and accounts receivable-trade 29,859 31,898 31,896 28,361 32,424 37,327 36,61 Electronically recorded monetary claims-operating 4,566 6,513 11,654 1,524 Marketable securities Merchandise and finished goods 1,133 1,913 11,397 12,578 12,918 13,241 13,946 Work in process 926 1,161 1,48 1,636 2,36 2,26 2,391 Raw materials and supplies 5,277 5,931 6,579 7,167 7,29 7,534 7,272 Deferred tax assets 3,383 3,539 4,69 3,63 3,455 3,796 4,53 Other 1,548 2,549 2,231 2,156 3,135 3,2 3,263 Allowance for doubtful accounts Fixed Assets 61,37 64,727 73,175 79,268 83,816 77,821 8,594 Property, plant and equipment 39,427 42,628 44,758 48,563 5,37 48,4 45,834 Buildings and structures 17,29 19,22 19,965 2,73 22,347 21,322 2,26 Machinery, equipment and vehicles 6,795 9,342 1,389 1,752 11,32 1,239 9,387 Equipment 1,37 1,187 1,587 2,351 2,39 2,144 1,863 Land 9,77 1,217 1,613 12,34 13,26 12,956 12,91 Construction in progress 4,46 2,782 2,97 2,25 1,153 1,224 1,325 Other Intangible fixed assets 2,492 2,273 2,8 2,828 4,376 3,52 2,663 Goodwill 1, ,326 1, Right of trademark Other 1,273 1,254 1,18 2,253 3,5 2,372 1,927 Investments and other assets 19,449 19,826 26,48 27,876 29,7 26,277 32,96 Investment securities 15,345 14,945 18,537 22,724 24,325 21,45 27,52 Deferred tax assets 2,35 2,452 2,697 2,59 1,944 1,815 1,617 Other 1,826 2,556 5,844 4, 4,173 4,742 5,261 Allowance for doubtful accounts ,374 1,686 2,284 Total assets 126, ,8 15, , ,59 179, ,543

11 Consolidated Balance Sheets (Summary) (millions of yen) LIABILITIES Current Liabilities 41,743 44,935 49,554 56,643 57,67 59,357 53,422 Notes and accounts payable-trade 9,121 1,525 1,151 11,753 1,21 12,355 12,151 Short-term loans payable 3,199 5,13 5,611 8,216 8,349 4,452 3,353 Accrued expenses 14,886 16,29 19,133 22,699 26,452 27,28 23,734 Accrued income taxes 3,587 2,755 2,914 2, ,645 2,551 Accrued consumption tax , Deposits received 3,217 2,798 2,648 Reserve for bonuses 1,885 1,861 1,979 1,99 1,854 2,64 2,92 Reserve for directors bonuses Reserve for returned goods unsold , , Reserve for rebates of sales 2,437 2,651 2,76 2,25 2,19 2,29 2,38 Other 2,231 2,185 2,617 5,869 5,726 5,647 5,918 Non-current Liabilities 6,817 7,445 7,316 6,979 9,385 8,944 9,684 Convertible bond / Long-term loans payable 2,716 3,335 1,578 1,666 1, ,765 Deferred tax liabilities 2,317 1,917 3,264 2,138 3,26 2,3 2,492 Net defined benefit liability 1,411 1,843 2,13 2,72 4,657 5,381 4,41 Reserve for directors retirement benefits Provision for loss on guarantees 789 Other Total Liabilities 48,561 52,38 56,871 63,622 66,993 68,31 63,17 NET ASSETS Owners Equity 79,159 85,475 91,341 92,869 99,13 15, ,517 Capital stock 6,398 6,45 6,48 6,411 6,411 6,411 6,415 Capital surplus 5,517 5,524 5,527 5,738 5,738 5,738 5,737 Retained earnings 67,511 73,814 79,677 86,55 92,315 98,675 16,32 Treasury stock ,785 5,451 5,27 4,938 Accumulated other comprehensive income 2,83 2,71 1,535 4,89 1,57 4,621 3,924 Valuation difference on available-for-sale securities 3,179 3,13 4,471 5,33 6,646 5,438 5,862 Foreign currency translation adjustment 4,953 5,133 2,239 1,47 5,479 1, Pension liability adjustment of foreign subsidiaries Remeasurements of defined benefit plans 1,27 1,618 2,113 1,498 Subscription rights to shares Non-controlling interests Total Net Assets 77,911 83,627 93,771 98,627 11, , ,436 Total Liabilities and Net Assets 126, ,8 15, , ,59 179, ,543 1

12 Consolidated Statements of Income (Summary) (millions of yen) Net sales 115,472 12, , , , ,16 154,599 Cost of sales 47,534 49,796 53,272 57,664 61,395 67,25 63,254 Selling, general and administrative expenses 54,832 56,871 61,493 69,336 77,44 83,543 75,893 Operating income 13,15 13,624 14,38 16,821 13,159 15,683 15,451 Non-operating income , ,135 Non-operating expenses , Ordinary income 13,293 13,684 14,73 17,1 14,98 15,339 15,964 Extraordinary income , ,329 Extraordinary loss ,42 3, ,17 2,541 Income before income taxes 13,43 14,88 13,63 14,599 13,751 14,33 14,752 Income taxes 5,493 5,944 5,528 5,651 5,123 5,217 4,738 Profit attributable to owners of parent 7,966 8,184 8,87 8,947 8,631 9,98 1,11 Consolidated Statements of Comprehensive Income (Summary) (millions of yen) Profit 7,936 8,144 8,11 8,948 8,627 9,85 1,13 Other comprehensive income Valuation difference on available-for-sale securities 1, , ,67 1, Foreign currency translation adjustment ,975 3,345 4,476 4,343 1,68 Changes in pension liability adjustment of foreign subsidiaries Remeasurements of defined benefit plans, net of tax Share of other comprehensive income of associates accounted for using equity method Total other comprehensive income 2, ,318 4,84 5,742 5, Comprehensive income 5,688 7,497 12,42 13,32 14,37 3,171 9,35 Comprehensive income attributable to Comprehensive income attributable to owners of the parent 5,75 7,566 12,374 12,973 14,329 3,212 9,333 Comprehensive income attributable to non-controlling interests

13 Consolidated Statements of Cash Flows (Summary) (millions of yen) Net cash provided by operating activities Income before income taxes 13,43 14,88 13,63 14,599 13,751 14,33 14,752 Depreciation and amortization 4,257 4,89 5,256 5,735 6,59 6,44 5,552 Impairment loss , Amortization of goodwill Increase (decrease) in allowance for doubtful accounts Increase (decrease) in reserve for bonuses Increase (decrease) in reserve for directors bonuses Increase (decrease) in net defined benefit liability Increase (decrease) in reserve for returned goods unsold Increase (decrease) in reserve for rebates of sales Interest and dividends income Interest expenses Equity in (earnings) losses of affiliates Decrease (increase) in notes and accounts receivable-trade 1,854 1,968 1, ,634 13,189 1,274 Decrease (increase) in inventories 1,481 1, , , Increase (decrease) in notes and accounts payable-trade 442 1, ,87 2,436 3, Other 2, ,358 3,862 2,561 1,762 1,785 Subtotal 17,697 16,494 21,748 24,21 16,428 13,348 18,953 Interest and dividends income received Interest expenses paid Income tax paid 4,835 6,314 5,36 5,877 5,471 2,957 6,14 Income taxes refund Net cash provided by operating activities 12,924 1,391 16,72 18,661 11,292 11,324 13,428 Net cash used in investment activities Payments into time deposits 566 1, Purchase of property, plant and equipment 8,462 8,276 5,13 6,278 3,964 4,563 3,777 Purchase of intangible fixed assets Purchase of investment securities 292 1,49 2,449 5, ,382 7,92 Proceeds from sales of investment securities 1, ,152 1,4 2,158 1,922 Net decrease (increase) in short-term loans receivable Other ,481 3,56 4, Net cash used in investment activities 8,587 9,65 1,595 12,62 9,24 6,66 9,511 Net cash used in financing activities Increase (decrease) in short-term loans payable , ,37 75 Proceeds from long-term loans payable 249 3, ,123 Repayment of long-term loans payable 2,269 1,122 2,292 2,31 1,28 1, Cash dividends paid 1,646 1,881 1,881 2,116 2,5 2,278 2,278 Other , Net cash used in financing activities 3,31 8 3,48 5,211 3,375 5,898 2,335 Effect of exchange rate change on cash and cash equivalents ,742 1,849 2,775 1, Increase (decrease) in cash and cash equivalents 732 1,375 4,441 2,678 1,667 2, Cash and cash equivalents at beginning of year 13,272 14,5 15,381 19,867 23,26 25,93 22,495 Increase in cash and cash equivalents from newly consolidated subsidiary Cash and cash equivalents at end of year 14,5 15,381 19,867 23,26 25,93 22,495 23,466 12

14 Non-Consolidated Financial Statements (Summary) (millions of yen) Non-Consolidated Balance Sheets ASSETS Current Assets 38,714 4,675 4,268 35,942 38,19 43,468 42,984 Fixed Assets 66,2 66,857 74,962 79,742 79,311 79,79 84,831 Total Assets 14,915 17, ,23 115, ,42 122, ,815 LIABILITIES Current Liabilities 26,728 26,234 27,675 3,742 26,861 29,64 27,357 Non-current Liabilities 1,91 1,479 2,31 2,23 3,617 2,643 3,755 Total Liabilities 28,639 27,714 29,986 32,946 3,478 31,77 31,112 NET ASSETS Owners Equity 72,494 76,216 8,321 5,738 79,766 84,851 9,292 Capital stock 6,398 6,45 6,48 6,411 6,411 6,411 6,415 Capital surplus 5,517 5,524 5,527 5,738 5,738 5,738 5,742 Retained earnings 6,846 64,556 68,657 7,773 73,67 77,98 83,73 Treasury stock ,785 5,451 5,27 4,938 Valuation and translation adjustments 3,188 3,22 4,349 5,31 6,66 5,42 5,849 Valuation difference on available-for-sale securities 3,188 3,22 4,349 5,31 6,66 5,42 5,849 Subscription rights to shares Total Net Assets 76,275 79,818 85,244 82,738 86,941 9,84 96,72 Total Liabilities and Net Assets 14,915 17, ,23 115, ,42 122, ,815 Non-Consolidated Statements of Income Net sales 77,215 77,59 82,754 84,434 82,218 89,264 89,561 Eye care products 23,89 22,116 23,583 23,254 22,618 24,486 25,233 Skincare products 42,279 44,359 47,161 49,562 49,83 53,347 53,792 Internal Medicines 8,417 8,29 8,47 8,992 7,844 8,361 8,451 Others 3,429 3,3 3,538 2,624 2,672 3,69 2,84 Cost of sales 3,166 3,23 31,68 31,94 31,827 34,718 35,66 Selling, general and administrative expenses 36,281 36,52 39,532 41,12 42,462 43,8 43,8 Operating income 1,767 1,965 11,613 11,651 8,148 1,695 1,695 Net non-operating income (expense) ,9 2,121 Ordinary income 11,275 11,53 12,132 12,277 9,132 12,75 12,817 Net extraordinary income (loss) 1 1,33 1,857 4,499 1,12 2, 2,222 Income before income taxes 11,273 1,226 1,275 7,778 8,12 1,75 1,594 Income taxes 4,48 4,634 4,292 3,545 3,112 3,586 3,152 Net income 6,865 5,591 5,983 4,232 5,7 7,118 7,442 13

15 Stock Information Shares Number of shares authorized (share) 399,396, Number of shares issued (share) 117,936,284 Number of shareholders (Year-over-year) 14,215(+1,451) Stock Price Trend and Trading Volume Stock Price Trend Stock price(yen) 2,8 2,4 (as of March 31, 217) Major Shareholders Shareholder Shareholdings(thousand shares) / Voting stake(%) The Master Trust Bank of Japan, Ltd. (Trust account) 7, Japan Trustee Services Bank, Ltd. (Trust account) 6, STATE STREET BANK AND TRUST COMPANY , The Bank of Tokyo-Mitsubishi UFJ, Ltd. 3, NORTHERN TRUST CO. (AVFC) RE SILCHESTER INTERNATIONAL INVESTORS INTERNATIONAL VALUE EQUITY TRUST 3, Kiyoko Yamada 2, Yamashou Kousan Co., Ltd. 2, STATE STREET BANK AND TRUST COMPANY 2, NORTHERN TRUST CO. (AVFC) RE U. S. TAX EXEMPTED PENSION FUNDS 2, Nippon Life Insurance Company 2, Note) The Holding Ratio has been calculated by deducting the treasury stock (4,18,778 stocks). The treasury stock does not include the Company 2,3 stocks which the employee stock ownership plan (ESOP) owns. 2, 1,6 1,2 8 Trading Volume (Thousand shares) 25, 15, 1, 5, Composition of Shareholders by Category Distribution of Shares by Number of Shares Held Treasury stock 4,18 thousand shares 3.41% Japanese individuals and others 28,818 thousand shares 24.44% Foreign investors 35,773 thousand shares 3.33% Japanese financial institutions 36,545 thousand shares 3.98% Japanese Financial Instruments Business Operators 933 thousand shares.79% Japanese companies and corporations 11,847 thousand shares 1.5% Distribution of Shares by Shareholder Type Treasury stock 1 person.1% Foreign investors 25 persons 1.76% Japanese individuals and others 13,752 persons 96.74% Japanese financial institutions 49 persons.34% Japanese Financial Instruments Business Operators 25 persons.18% Japanese companies and corporations 138 persons.97% 14

16